ADMA
NASDAQ · Biotechnology
Adma Biologics Inc
$8.17
-0.30 (-3.54%)
Financial Highlights (FY 2026)
Revenue
511.17M
Net Income
147.21M
Gross Margin
57.4%
Profit Margin
28.8%
Rev Growth
+49.0%
D/E Ratio
0.15
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 57.4% | 57.4% | 49.6% | 49.6% |
| Operating Margin | 36.9% | 33.2% | -9.0% | -9.9% |
| Profit Margin | 28.8% | 27.4% | -10.4% | -8.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 511.17M | 342.98M | 922.90M | 1.03B |
| Gross Profit | 293.36M | 196.83M | 457.58M | 508.40M |
| Operating Income | 188.47M | 113.81M | -82,955,088 | -101,708,220 |
| Net Income | 147.21M | 88.89M | -95,808,796 | -87,264,834 |
| Gross Margin | 57.4% | 57.4% | 49.6% | 49.6% |
| Operating Margin | 36.9% | 33.2% | -9.0% | -9.9% |
| Profit Margin | 28.8% | 27.4% | -10.4% | -8.5% |
| Rev Growth | +49.0% | +49.0% | +20.1% | +10.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 131.58M | 131.58M | 1.56B | 1.50B |
| Total Equity | 870.83M | 870.83M | 2.42B | 2.53B |
| D/E Ratio | 0.15 | 0.15 | 0.64 | 0.59 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 188.41M | 120.10M | -107,012,515 | -125,992,506 |
| Free Cash Flow | — | — | -83,155,340 | -96,884,239 |